Maribavir isomers, compositions, methods of making and methods of using

Abstract

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

Claims

1. A composition comprising maribavir and at least one of an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir, (ii) an antibiotic having activity against a microorganism that mediates isomerization of maribavir, or (iii) an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of maribavir.

2. The composition of claim 1, wherein said composition comprises maribavir and an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir.

3. The composition of claim 1, wherein said composition comprises maribavir and an antibiotic having activity against a microorganism that mediates isomerization of maribavir.

4. The composition of claim 1, wherein said composition comprises maribavir and an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of maribavir.

5. The composition of claim 1, wherein said composition comprises at least 100 mg of maribavir.

6. The composition of claim 5, wherein said composition comprises up to 3200 mg of maribavir.

7. The composition of claim 1, wherein said composition is an immediate release formulation, a delayed release formulation, a controlled release formulation or an intravenous formulation.

8. The composition of claim 1, wherein said composition is formulated for oral administration.

9. The composition of claim 1, wherein said composition is formulated for intravenous administration.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows chemical structures of maribavir and maribavir configurational stereoisomers that have the same configuration at the furanoysl anomer carbon.

(2) FIG. 2 shows chemical structures of maribavir configurational stereoisomers that have the opposite configuration at the furanosyl anomer carbon.

(3) FIG. 3 shows chemical structures of maribavir pyranosyl constitutional isomers)

(4) A number of patent and non-patent documents are cited in the foregoing specification in order to describe the state of the art to which this invention pertains. The entire disclosure of each of these citations is incorporated by reference herein.

(5) While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims. Furthermore, the transitional terms comprising, consisting essentially of and consisting of define the scope of the appended claims, in original and amended form, with respect to what unrecited additional claim elements or steps, if any, are excluded from the scope of the claims. The term comprising is intended to be inclusive or open-ended and does not exclude additional, unrecited elements, methods step or materials. The phrase consisting of excludes any element, step or material other than those specified in the claim, and, in the latter instance, impurities ordinarily associated with the specified materials. The phrase consisting essentially of limits the scope of a claim to the specified elements, steps or materials and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. All compositions or formulations identified herein can, in alternate embodiments, be more specifically defined by any of the transitional phases comprising, consisting essentially of and consisting of.